ONXEO.CO - Onxeo SA
| Previous close | 1.2000 |
| Open | 1.1840 |
| Bid | 1.3000 x 0 |
| Ask | 1.3500 x 0 |
| Day's range | 1.1700 - 1.3800 |
| 52-week range | 1.1700 - 3.0000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 166.932M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Onxeo: Combined General Meeting of June 6, 2023: Availability of Preparatory Documents and Participation & Voting Procedures
PARIS, May 16, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the availability of preparatory documents for its Combined General Meeting to be held on Tuesday, June 6, 2023 at 2:00 pm at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris.
- Business Wire
Onxeo: Publication of the 2022 Annual Financial Report
PARIS, April 28, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the publication of the Company’s 2022 annual financial report.
- Business Wire
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
PARIS, April 24, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2022.
- Business Wire
Onxeo will publish its full-year results on April 24, 2023
PARIS, April 21, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022 full-year results.
- Business Wire
Onxeo Will Publish Its Full-year Results on April 21, 2023
PARIS, April 14, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022 full-year results.
- Business Wire
Onxeo Will Publish Its Full-year Results on April 14, 2023
PARIS, March 14, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new dates for the publication of its 2022 full-year results and the holding of its annual general meeting.
- Business Wire
Onxeo: Report on the Extraordinary General Meeting of February 6, 2023
PARIS, February 06, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Extraordinary General Meeting (EGM) held today at 2 pm was able to validly deliberate with a quorum of 44.35%.
- Business Wire
Onxeo Announces its Financial Agenda for 2023
PARIS, January 27, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced its financial agenda for 2023.
- Business Wire
ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
PARIS, January 25, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM.
- Business Wire
Onxeo: Extraordinary General Meeting of February 6, 2023: Availability of Preparatory Documents
PARIS, January 18, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, today announces the availability of the preparatory documents for its Extraordinary General Meeting which will be held on Monday, February 6, 2023 at 2:00 p.m. at the Renaissance Paris Nobel Tour Eif
- Business Wire
Half-year liquidity contract statement for ONXEO
PARIS, January 04, 2023--Regulatory News: Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31, 2022:
- Business Wire
Onxeo Advances Its Second Lead Candidate OX425 for the Treatment of Solid Tumors
PARIS, November 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces the expansion of its pipeline of drug candidates with OX425, the optimized new compound of OX400 series sourced from its proprietary PlatON™ platform.
- Business Wire
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
PARIS, September 13, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen1: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2022 and provides an update on its activities.
- Business Wire
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie
PARIS, September 01, 2022--Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR)n in particular against rare or resistant forms of cancer, today announced that the first patient has been enrolled and treated in the phase 1b/2 clinical study that aims to evaluate the efficacy and tolerability of AsiDNA2, Onxeo’s first-in-class DDR inhibit
- Business Wire
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen
PARIS, August 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced that Nasdaq approved the removal of shares from First North Growth trading.
- Business Wire
Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen
PARIS, August 17, 2022--Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced that the Combined General Meeting held today has adopted all the resolutions presented in line with the recommendations of the Board of Directors.
- Business Wire
Onxeo S.A.: Combined General Meeting of August 17, 2022: Availability of Preparatory Documents and Participation & Voting Procedures
PARIS, July 29, 2022--Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO) (Paris:ALONX) (NASDAQ OMX:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced the availability of the preparatory documents for its Combined General Meeting of August 17, 2022.
- Business Wire
Onxeo Announces a Combined General Meeting on August 17, 2022
PARIS, July 12, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces that it will hold a Combined General Meeting on Wednesday, August 17, 2022 at 2:00 pm CEST at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris.
- Business Wire
Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux
PARIS, July 04, 2022--Regulatory News: Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- Business Wire
Onxeo: Initial IND Application for AsiDNA Granted "Study May Proceed" by the U.S. FDA
PARIS, June 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced that the U.S. Food and Drug Administration (FDA) has cleared the initial IND for its first-in-class drug candidate AsiDNA. This is the first US IND Onxeo filed since the US team came on board in
- Business Wire
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
PARIS, June 16, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), ("Onxeo" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held today adopted all resolutions presented, in accordance with the Board of Directors’ recommendations.
